Ototoxicity Rates in Children Receiving Carboplatin Studied

This article originally appeared here.
Ototoxicity Rates in Children Receiving Carboplatin Studied
Ototoxicity Rates in Children Receiving Carboplatin Studied

(HealthDay News) -- Retinoblastoma patients who are younger than 6 months of age at the start of carboplatin treatment experience a higher incidence of ototoxicity, according to a study published online Feb. 27 in the Journal of Clinical Oncology.

Ibrahim Qaddoumi, M.D., of the St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues reviewed the results of audiologic tests for 60 patients with retinoblastoma who received front-line treatment with systemic carboplatin and vincristine according to either the St. Jude RET-3 protocol (23 patients) or best clinical management (37 patients). Three different ototoxicity grading systems were used.

The researchers found that 12 patients (20 percent) developed ototoxicity at some point following initiation of treatment; ototoxicity resolved in two patients, leaving 10 patients (17 percent) with sustained hearing loss. Nine of these 10 patients had grade 3 or 4 ototoxicity. Ninety percent of the 10 patients with hearing loss were less than 6 months of age at the start of chemotherapy. Age at the start of chemotherapy was the only risk factor that significantly predicted sustained hearing loss, and younger age was associated with an increased incidence of hearing loss. The different ototoxicity grading systems showed good overall agreement for identifying otoxicity, and agreement was greatest between the Brock and Children's Cancer Group systems.

"Young patients with retinoblastoma who were treated with systemic carboplatin had a higher incidence of ototoxicity than previously reported," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs